You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Selected published results of SRS (2000–2015) for the treatment of prolactin-secreting pituitary adenomas

From: Target delineation and optimal radiosurgical dose for pituitary tumors

Authors Patients Type dose Follow-up Tumor Biochemical Late toxicity (%)
of SRS (Gy) (months) control (%) remission (%) visual hypopituitarism
Landolt 2000 [124] 20 GK 29 25 85 25 0 NA
Pan L et al., 2000 [125] 128 GK 33 41 99 41 0 NA
Izawa et al., 2000 [85] 15 GK 23.6 16 100 16 0 NA
Feigl et al., 2002 [32] 18 GK 15a 55 94 60 NA 40
Choi et al., 2003 [126] 21 GK 28.5a 42.5 96.9 23.8 0 0
Petrovich et al., 2003 [60] 12 GK 15a 41 83 83 0 4
Pouratian et al., 2006 [127] 23 GK 18.6a 55 89 26 7 28
Voges et al., 2006 [66] 13 LINAC 20 56 100 15.4 4.2 18.3
Pollock et al., 2008 [118] 11 GK 18a 48 100 18 at 4 years 9.1 36
Castinetti et al., 2009 [100] 15 GK 28a 96 100 46.6 0 21
Jezkova et al., 2009 [128] 35 GK 34a 75.5 97 37.1 0 14.3
Wan et al., 2009 [98] 176 GK 22.4a 67.5 90.3 23.3 0 1.8
Tanaka et al., 2010 [129] 22 GK 25a 60 100 18 4 42 at 4 years
Sheehan et al., 2011 [36] 32 GK 24a 31 93 26 2.4 24.4
Liu et al., 2013 [130] 22 GK 15a 36 86 27.3 0 4.5
Wattson et al., 2014 [109] 9 Protons 20 60 98 22 0 57
Cohen-Inbar et al., 2015 [131] 38 GK 25a 42.3 92 50 4.2 30.3
  1. SRS stereotactic radiosurgery, GK Gamma Knife, LINAC Linear Accelerator, CK CyberKnife, NA not assessed
  2. amarginal dose